Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million

Reuters

昨天

<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million

Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.
Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the Gilead license tied to a development milestone.
Q4 R&D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.
Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.
Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676136) on March 23, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2621770766"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621770766\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621770766?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621770766","market":"fut","top_or_hot":-1,"title":"Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/XLO\">Xilio Therapeutics</a> Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.\n        </li>\n<li>\n          Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the <a href=\"https://laohu8.com/S/GILD\">Gilead</a> license tied to a development milestone.\n        </li>\n<li>\n          Q4 R&amp;D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.\n        </li>\n<li>\n          Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676136) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-23 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/XLO\">Xilio Therapeutics</a> Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.\n        </li>\n<li>\n          Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the <a href=\"https://laohu8.com/S/GILD\">Gilead</a> license tied to a development milestone.\n        </li>\n<li>\n          Q4 R&amp;D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.\n        </li>\n<li>\n          Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.\n        </li>\n<li>\n          Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676136) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739343.SGD","symbol_name":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL77HrJ1:1","article_id":"2621770766","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621770766","pubTimestamp":1774265500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the Gilead license tied to a development milestone.Q4 R&D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","GILD":"吉利德科学","XLO":"XILIO THERAPEUTICS, INC.","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","BK4566":"资本集团","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4578":"CAR-T","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4559":"巴菲特持仓","ABBV":"艾伯维公司","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","NDAQ":"纳斯达克OMX交易所","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4583":"猴痘概念","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC"},"translate_title":"Xilio Therapeutics Q4许可收入增长100%至1400万美元，净收入1000万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"NDAQ":0.9,"GILD":0.9,"XLO":0.9},"content_text":"Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million\n    \n\n\n          Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.\n        \n\n          Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the Gilead license tied to a development milestone.\n        \n\n          Q4 R&D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.\n        \n\n          Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.\n        \n\n          Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676136) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}